Rachel Lydon

Cooley advised Grafana Labs, the company behind ubiquitous, open and composable operational dashboards, on the successful completion of its approximately $270 million primary and secondary transaction.

Cooley advised Abnormal Security, a leading artificial intelligence-based cloud-native email security platform, on its $210 million Series C financing round, which brings the company’s valuation to $4 billion. Lawyers Josh Seidenfeld, Nan Yang, Rachel Lydon and Kaavya Gowda led the Cooley team advising Abnormal Security.

Cooley advised Grafana Labs, the company behind the world’s most ubiquitous open and composable operational dashboards, on the closing of its $240 million Series D funding round. Lawyers Kevin Rooney, Mary Wilbourn, Rachel Lydon and Will Siroky led the Cooley team advising Grafana Labs.

Cooley advised Grafana Labs, the company behind the world’s most ubiquitous open and composable operational dashboards, on its $220 million Series C financing round, which brings its valuation to $3 billion. Lawyers Kevin Rooney and Mary Wilbourn led the Cooley team advising Grafana Labs.

Cooley advised Rani Therapeutics on its $73.3 million initial public offering of 6,666,667 shares of Class A common stock. Rani Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol RANI, is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Partners Josh Seidenfeld, Mark Weeks, John McKenna and Charlie Kim led the Cooley team.